drugset / Trial / NCT02689856

Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids

NCT02689856

Phase 2 Completed 211 enrolled Citius Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to assess the potential contribution of lidocaine hydrochloride or hydrocortisone acetate, alone or in combination, in topical cream preparations in the treatment of Grade I or II hemorrhoids and to demonstrate the safety and efficacy of the test articles when applied twice daily for 14 days in subjects with Grade I or II hemorrhoids. These products reflect common drug combinations of lidocaine hydrochloride or hydrocortisone acetate found in many prescription hemorrhoid products.

Timeline

Start
2015-05
Primary completion
2015-09
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 0.5 % Topical
Subject Hydrocortisone Other / unclassified 3 % Topical
Subject Lidocaine Other / unclassified 1 % Topical
Subject Lidocaine Other / unclassified 5 % Topical

Indications